Corvus Pharmaceuticals (CRVS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.19
- Estimate
- -$0.17
- Surprise
- -13.4%
- Score today
- 5.2/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Corvus Pharmaceuticals (CRVS) reported a wider loss than forecast — diluted EPS of -$0.19 against the -$0.17 estimate (a 13.4% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRVS Sell at 5.2/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's -13.4% surprise compares with a -3.3% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Pipeline: soquelitinib
- Concentration risk — Supplier: mupadolimab manufacturer
- Quality below floor (1.6 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.35
- Price target
- $28.83
- Stop
- $13.41
- Upside to target
- +100.9%
- Reward-to-risk
- 10.7:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
CRVS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.23B
- P/E (fwd)
- -13.7
- 52-week range
- $5.64–$26.95
- Off 52-week high
- 46.8%
- RSI (14)
- 45
- Volume vs avg
- 0.57×
- Score today
- 5.2/10